NCT00152295View on ClinicalTrials.gov

A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
Postmenopause
Interventions
DRUG

Asoprisnil/Premarin

10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY